aTyr Pharma (NASDAQ:LIFE) Stock Price Down 9.9%

aTyr Pharma, Inc. (NASDAQ:LIFE)’s stock price was down 9.9% during trading on Tuesday . The stock traded as low as $4.22 and last traded at $4.65. Approximately 807,884 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 1,320,219 shares. The stock had previously closed at $5.16.

Separately, Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Friday, January 29th.

The stock’s 50-day moving average is $4.67 and its 200-day moving average is $3.99. The firm has a market capitalization of $47.36 million, a price-to-earnings ratio of -1.69 and a beta of 2.17.

A number of hedge funds have recently added to or reduced their stakes in LIFE. Ikarian Capital LLC acquired a new position in aTyr Pharma during the 4th quarter worth approximately $1,552,000. Alyeska Investment Group L.P. increased its position in aTyr Pharma by 11.9% during the 4th quarter. Alyeska Investment Group L.P. now owns 842,554 shares of the biotechnology company’s stock worth $3,269,000 after purchasing an additional 89,908 shares in the last quarter. Ardsley Advisory Partners LP acquired a new position in aTyr Pharma during the 3rd quarter worth approximately $65,000. Acadian Asset Management LLC increased its position in aTyr Pharma by 22.2% during the 3rd quarter. Acadian Asset Management LLC now owns 83,052 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 15,088 shares in the last quarter. Finally, BlackRock Inc. increased its position in aTyr Pharma by 23.8% during the 3rd quarter. BlackRock Inc. now owns 41,411 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 7,948 shares in the last quarter. Institutional investors and hedge funds own 55.82% of the company’s stock.

About aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial.

Read More: Green Investing